EvolvRehab for Telerehabilitation

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

May 4, 2024

Study Completion Date

May 4, 2024

Conditions
Stroke
Interventions
DEVICE

EvolvRehab - MoveWell

The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training \[training package\]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.

Trial Locations (1)

Unknown

Royal Devon and Exeter Hospitals, Exeter

All Listed Sponsors
lead

University of Exeter

OTHER

NCT05875792 - EvolvRehab for Telerehabilitation | Biotech Hunter | Biotech Hunter